Fierce Pharma8d
Paratek acquires Optinose, rhinosinusitis spray Xhance in deal worth up to $330M
In a move to expand its portfolio beyond antibiotics, Paratek Pharmaceuticals has bought out Optinose and its chronic ...
Optinose to be acquired by Boston-based Paratek Pharmaceuticals in potential $330M deal
The website you are visiting is protected and accelerated by Imperva. Your computer may have been infected by malware and ...
Business Insider8d
Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE® in Chronic Rhinosinusitis (CRS)
BOSTON and YARDLEY, Pa., March 19, 2025 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals and Optinose, Inc. (NASDAQ:OPTN) today announced they have entered into a definitive merger agreement under which ...
Paratek Pharmaceuticals to acquire Optinose in $330M transaction
Paratek Pharmaceuticals (PRTK) and Optinose (OPTN) announced they have entered into a definitive merger agreement under which Paratek will ...
Optinose Shares Surge Premarket on Takeover Deal With Paratek
Optinose shares took flight in premarket trading Thursday after the pharmaceutical company agreed to be acquired by privately held Paratek Pharmaceuticals in a deal worth up to $330 million.
The National Law Review10d
Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE® in Chronic Rhinosinusitis (CRS)
March 19, 2025 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals and Optinose, Inc. (NASDAQ:OPTN) today announced they have entered into a definitive merger agreement under which Paratek will acquire ...